Wieczorke Roman, Dlugai Silke, Krampe Stefanie, Boles Eckhard
Institute für Mikrobiologie, Heinrich-Heine-Universität, Düsseldorf.
Cell Physiol Biochem. 2003;13(3):123-34. doi: 10.1159/000071863.
We have developed a new heterologous expression system for mammalian glucose transporters. The system is based on a Saccharomyces cerevisiae strain completely deleted for all its endogenous hexose transporters and unable to take up and to grow on hexoses. To target the heterologous glucose transporters into the yeast plasma membrane in a fully active form, additional mutations had to be introduced into the hexose transport-deficient strain. Although GLUT1 was localized at the cell surface already in the parent strain, it supported uptake of glucose only in an deltaHXT FGY1-1 mutant strain. Moreover, various mutations within the first half of the second predicted transmembrane helix converted GLUT1 into a form able to support uptake of glucose into yeast cells. GLUT4 was trapped in intracellular structures but became functionally expressed in the plasma membrane in deltaHXT FGY1-1 FGY4X mutant strains. Glucose transport kinetics were determined with intact yeast cells by zero-trans influx measurements with a Km of 3.2 mM for human GLUT1 and of 12.6 mM for human GLUT4. Cytochalasin B inhibited these activities. Growth tests revealed that both transporter proteins are able to mediate uptake of glucose, mannose and galactose, but not of fructose. The new heterologous expression system should be a valuable tool to develop cell based high-throughput screening assays for identifying pharmaceutical compounds influencing the transporters.
我们已经开发出一种用于哺乳动物葡萄糖转运蛋白的新型异源表达系统。该系统基于一种酿酒酵母菌株,其所有内源性己糖转运蛋白均被完全删除,无法摄取己糖并在己糖上生长。为了将异源葡萄糖转运蛋白以完全活性的形式靶向酵母质膜,必须在己糖转运缺陷型菌株中引入额外的突变。尽管GLUT1在亲本菌株中已经定位于细胞表面,但它仅在ΔHXT FGY1-1突变菌株中支持葡萄糖的摄取。此外,第二个预测跨膜螺旋前半部分的各种突变将GLUT1转化为一种能够支持葡萄糖摄取到酵母细胞中的形式。GLUT4被困在细胞内结构中,但在ΔHXT FGY1-1 FGY4X突变菌株的质膜中功能性表达。通过零转运流入测量法,用完整的酵母细胞测定葡萄糖转运动力学,人GLUT1的Km为3.2 mM,人GLUT4的Km为12.6 mM。细胞松弛素B抑制了这些活性。生长试验表明,两种转运蛋白都能够介导葡萄糖、甘露糖和半乳糖的摄取,但不能介导果糖的摄取。这种新的异源表达系统应该是开发基于细胞的高通量筛选试验以鉴定影响转运蛋白的药物化合物的有价值工具。